Data availability
Not applicable.
References
Del Buono MG, Bonaventura A, Vecchie A, Moroni F, Golino M, Bressi E, De Ponti R, Dentali F et al (2023) Pathogenic pathways and therapeutic targets of inflammation in heart diseases: a focus on Interleukin-1. Eur J Clin Invest. https://doi.org/10.1111/eci.14110
Thurner L, Kessel C, Fadle N, Regitz E, Seidel F, Kindermann I, Lohse S, Kos I et al (2022) IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N Engl J Med 387:1524–1527. https://doi.org/10.1056/NEJMc2205667
Malandrino D, Bello F, Lopalco G, Cantarini L, Olivotto I, Emmi G, Prisco D (2023) Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis. Intern Emerg Med. https://doi.org/10.1007/s11739-023-03514-2
Lazzerini PE, Abbate A, Boutjdir M, Capecchi PL (2023) Fir(e)ing the rhythm: inflammatory cytokines and cardiac arrhythmias. JACC Basic Transl Sci 8:728–750. https://doi.org/10.1016/j.jacbts.2022.12.004
Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, Aegisdottir HM, Oddsson A, Stefansson OA, Halldorsson GH, Saevarsdottir S et al (2023) Variants at the Interleukin 1 gene locus and pericarditis. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2023.4820
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wu, M.A., Bizzi, E. & Brucato, A. Exploring IL-1 inhibition in chronic refractory idiopathic myocarditis: emerging insights and perspectives. Intern Emerg Med 19, 273–274 (2024). https://doi.org/10.1007/s11739-024-03552-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-024-03552-4